Gene therapy used for tissue engineering applications

被引:36
作者
Heyde, Mieke
Partridge, Kris A.
Oreffo, Richard O. C.
Howdle, Steven M.
Shakesheff, Kevin M.
Garnett, Martin C.
机构
[1] Univ Nottingham, Sch Pharm, Div Adv Drug Delivery & Tissue Engn, Nottingham NG7 2RD, England
[2] Univ Southampton, Bone & Joint Res Grp, Gen Hosp, Southampton SO16 6YD, Hants, England
[3] Univ Nottingham, Sch Chem, Clean Technol Grp, Nottingham NG7 2RD, England
基金
英国生物技术与生命科学研究理事会;
关键词
D O I
10.1211/jpp.59.3.0002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review highlights the advances at the interface between tissue engineering and gene therapy. There are a large number of reports on gene therapy in tissue engineering, and these cover a huge range of different engineered tissues, different vectors, scaffolds and methodology. The review considers separately in-vitro and in-vivo gene transfer methods. The in-vivo gene transfer method is described first, using either viral or non-viral vectors to repair various tissues with and without the use of scaffolds. The use of a scaffold can overcome some of the challenges associated with delivery by direct injection. The ex-vivo method is described in the second half of the review. Attempts have been made to use this therapy for bone, cartilage, wound, urothelial, nerve tissue regeneration and for treating diabetes using viral or non-viral vectors. Again porous polymers can be used as scaffolds for cell transplantation. There are as yet few comparisons between these many different variables to show which is the best for any particular application. With few exceptions, all of the results were positive in showing some gene expression and some consequent effect on tissue growth and remodelling. Some of the principal advantages and disadvantages of various methods are discussed.
引用
收藏
页码:329 / 350
页数:22
相关论文
共 140 条
[31]  
2-1
[32]   Stimulation of new bone formation by direct transfer of osteogenic plasmid genes [J].
Fang, JM ;
Zhu, YY ;
Smiley, E ;
Bonadio, J ;
Rouleau, JP ;
Goldstein, SA ;
McCauley, LK ;
Davidson, BL ;
Roessler, BJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) :5753-5758
[33]   Protective copolymers for nonviral gene vectors: synthesis, vector characterization and application in gene delivery [J].
Finsinger, D ;
Remy, JS ;
Erbacher, P ;
Koch, C ;
Plank, C .
GENE THERAPY, 2000, 7 (14) :1183-1192
[34]  
Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59
[35]  
Garnett MC, 1999, CRIT REV THER DRUG, V16, P147
[36]   Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro [J].
Gersbach, CA ;
Byers, BA ;
Pavlath, GK ;
Guldberg, RE ;
García, AJ .
BIOTECHNOLOGY AND BIOENGINEERING, 2004, 88 (03) :369-378
[37]   High-efficiency non-viral transfection of primary chondrocytes and perichondrial cells for ex-vivo gene therapy to repair articular cartilage defects [J].
Goomer, RS ;
Deftos, LJ ;
Terkeltaub, R ;
Maris, T ;
Lee, MC ;
Harwood, FL ;
Amiel, D .
OSTEOARTHRITIS AND CARTILAGE, 2001, 9 (03) :248-256
[38]  
Goomer RS, 2000, CLIN ORTHOP RELAT R, pS189
[39]   Stem cells as platforms for delivery of genes to enhance cartilage repair [J].
Grande, DA ;
Mason, J ;
Light, E ;
Dines, D .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2003, 85A :111-116
[40]   Wound healing: The role of growth factors [J].
Grazul-Bilska, AT ;
Johnson, ML ;
Bilski, JJ ;
Redmer, DA ;
Reynolds, LP ;
Abdullah, A ;
Abdullah, KM .
DRUGS OF TODAY, 2003, 39 (10) :787-800